MedTrace Logo

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2014-07-03

No results posted yet for this study

Summary

A thorough QT study of AZD3293

Conditions

Interventions

DRUG

AZD3293

AZD3293 oral solution - one single dose (low dose).

DRUG

AZD3293

AZD3293 oral solution - one single dose (high dose).

DRUG

Placebo

Placebo oral solution - one single dose

DRUG

Moxifloxacin

Moxifloxacin tablet - one single dose

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Ronald Goldwater, MD · Parexel ECPU Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040987 on ClinicalTrials.gov